TCGA-A8-A06U-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 29
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.430
- PROTEIN_SECRETION+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.380
- INTERFERON_GAMMA_RESPONSE+0.360
- MYC_TARGETS_V2+0.360
- MTORC1_SIGNALING+0.340
- E2F_TARGETS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- MYOGENESIS-0.380
- ANGIOGENESIS-0.370
- UV_RESPONSE_DN-0.370
- WNT_BETA_CATENIN_SIGNALING-0.340
- APICAL_SURFACE-0.300
- TGF_BETA_SIGNALING-0.270
- COAGULATION-0.260
- TNFA_SIGNALING_VIA_NFKB-0.260
- APICAL_JUNCTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.877 |
| 2 | SRR975555 | — | — | 0.874 |
| 3 | SRR6013515 | — | cohortA4 | 0.848 |
| 4 | TCGA-AR-A0TV-01A-21R-A084-07 | — | B | 0.838 |
| 5 | TCGA-A8-A09M-01A-11R-A00Z-07 | — | B | 0.837 |
| 6 | SRR17866821 | — | — | 0.837 |
| 7 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.834 |
| 8 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.832 |
| 9 | TCGA-A2-A0YT-01A-11R-A109-07 | — | B | 0.827 |
| 10 | SRR27320678 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |